CPBTD
NVCR icon

Central Pacific Bank - Trust Division’s NovoCure NVCR Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76 Buy
+5
New +$76 ﹤0.01% 880

Other funds holding NVCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Central Pacific Bank - Trust Division's NVCR Position: Q2 2026 in Review

Central Pacific Bank - Trust Division opened a new position in NovoCure (NVCR) in Q2 2026: 5 shares worth $76. The stake represents ﹤0.01% of the portfolio and ranks #880 among its holdings.

84 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Central Pacific Bank - Trust Division held 5 shares of NovoCure worth $76 as of Q2 2026.
  • NovoCure was a new Central Pacific Bank - Trust Division position in Q2 2026.
  • NovoCure made up ﹤0.01% of Central Pacific Bank - Trust Division's portfolio in Q2 2026, its #880 holding.
  • 84 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Central Pacific Bank - Trust Division's 13F filing for Q2 2026, filed 7 Jul 2026.